All news from Anaesthesiology

Biorelevant nanomaterials synthesis

Artificial polyelectrolytes can mimic the interactions of biological macromolecules such as nucleic acids, proteins, and polysaccharide-protein conjugates. Such synthetic polyionic complexes are expected to serve as novel platforms to stabilize and deliver drugs, proteins, or nucleic acids. In the journal Angewandte Chemie, Chinese investigators have introduced a versatile, commercially applicable preparation strategy of such nanomaterials with tunable morphology. The preparation of libraries of these low-dimensional bio-relevant nanostructures can be envisaged.

PlaqueTec Liquid Biopsy System Feasible to detect Biomarkers for CAD

New open?access article published in the 1 issue of the Journal of the American College of Cardiology [JACC] has revealed the feasibility and potential of the PlaqueTec Liquid Biopsy System™ (LBS) to detect biomarkers for coronary artery disease (CAD). The system reported results from the first?in?human studies of the LBS in detecting biomolecular gradients in diseased coronary arteries of symptomatic patients undergoing percutaneous coronary intervention (PCI) procedures.  

Discover the disorder first, biochemists suggest

The sequencing of the human genome has made it possible. The biochemists confirmed the cause of initially unclear symptoms of patients in Israel. Such a disorder is 'MPS III-E', originally also called 'Dierks's disorder' after its discoverer. The researchers are now presenting their analysis in the journal Genetics in Medicine, published by the Nature Publishing Group.

EPC Scale could be Used in General Medicine

In a new study, researchers have validated the 'Escala de Preocupación por el Cáncer – EPC' (an equivalent of the Cancer Worry Scale) to evaluate the fear of suffering from cancer. The study, published in Medicina Clínica, has revealed that the EPC is a valid and reliable scale for evaluating concern about cancer in healthy people.

Patients with High-Risk RCC do not Benefit from Lymphadenectomy

In an ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial, researchers compared two different kinase inhibitors used in the setting with a placebo control arm. The trial sought to find whether removing any suspicious lymph nodes at the time of the nephrectomy might improve results. The team aimed at to wipe out any remaining micrometastatic disease and the results of the analysis are published in the Journal of Urology.